Loading organizations...
§ Private Profile · Beijing, Beijing, China
AI healthcare technology company developing AI-assisted diagnosis systems to enhance medical imaging and early detection of diseases.
Deepwise is a Beijing, China-based medical technology company that develops artificial intelligence-assisted diagnosis systems and radiomics research platforms for healthcare providers. The company provides intelligent imaging cloud solutions and multi-agent collaboration platforms designed to improve the early detection of diseases such as lung cancer and breast cancer across hospitals and diagnostic centers. Additionally, the enterprise has expanded its software offerings to support AI-driven drug discovery and clinical research for pharmaceutical development. Deepwise has raised $46.45 million in total venture capital funding, including a recent Series D round, backed by prominent institutional investors such as CDH Baifu, New Summit Capital, and Sequoia China. The organization previously reported a research and development team of over 60 employees to build its multimodal medical platforms. Deepwise was founded in 2017 by co-founders Qiao Xin and Yu Yizhou.
Deepwise has raised $50.0M across 2 funding rounds.
Deepwise has raised $50.0M in total across 2 funding rounds.
Deepwise has raised $50.0M in total across 2 funding rounds.
Deepwise's investors include Kangjun Capital, CDH Investments, Hongshan Capital Group (Sequoia Capital China), New Summit Capital.
Deepwise has raised $50.0M across 2 funding rounds. Most recently, it raised Deepin Medical - Series A in February 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 3, 2026 | Series A | Kangjun Capital | — | Announced |
| Dec 11, 2025 | $50M Series D | CDH Investments | Hongshan Capital Group (Sequoia Capital China), NEW Summit Capital | Announced |